BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 12, 2010
 |  BioCentury  |  Strategy

Stahel sees Scale in India

Ex-Shire CEO Stahel brings business acumen to Indian diabetes play Connexios

Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline of compounds against novel targets backed by a strong understanding of disease biology. The scale of the company's research team has attracted Rolf Stahel as non-executive chairman to add international business development and marketing acumen to the science that is already in development.

Like other small biotechs, Connexios hopes to fill the gap at pharma companies such as AstraZeneca plc that have become more dependent upon in-licensing to offset cuts in their own discovery research (see BioCentury, March 15).

Developing relationships with pharma and big biotech is where Stahel will play a role. Stahel became CEO of Shire plc in 1994 following 27 years at Burroughs Wellcome Co. (now GlaxoSmithKline plc). At the time, Shire had 15 employees and about $1 million in revenue, with a valuation of around $30 million. When he left in 2003, Shire had annual revenues exceeding $1.2 billion, more than 1,800 employees and a $4.8 billion market cap.

After leaving...

Read the full 877 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >